Niagen Bioscience
NAGE
91 hedge funds and large institutions have $64.3M invested in Niagen Bioscience in 2024 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 27 increasing their positions, 17 reducing their positions, and 8 closing their positions.
192% more call options, than puts
Call options by funds: $467K | Put options by funds: $160K
150% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 8
59% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 17
42% more capital invested
Capital invested by funds: $45.2M → $64.3M (+$19.1M)
15% more funds holding
Funds holding: 79 → 91 (+12)
1.3% more ownership
Funds ownership: 21.91% → 23.21% (+1.3%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$879K |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$849K |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$538K |
| 4 |
Morgan Stanley
New York
|
+$295K |
| 5 |
BWP
BSW Wealth Partners
Boulder,
Colorado
|
+$280K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$525K |
| 2 |
GI
GAMCO Investors
Greenwich,
Connecticut
|
-$283K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$254K |
| 4 |
Man Group
London,
United Kingdom
|
-$203K |
| 5 |
Invesco
Atlanta,
Georgia
|
-$167K |
NAGE Hedge Fund Activity: Q3 2024 in Review
91 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Niagen Bioscience (NAGE) for Q3 2024, worth a combined $64.3M — up 42% from $45.2M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new NAGE positions and 8 closed out — a net gain of 12 holders — while 27 added to existing stakes and 17 trimmed.
The largest buyer was BlackRock, adding an estimated $879K. The largest seller was Millennium Management, exiting entirely with an estimated $525K sold.
- 91 institutional investors held Niagen Bioscience (NAGE) as of Q3 2024, up from 79 in Q2 2024.
- Funds reported $64.3M of Niagen Bioscience stock for Q3 2024, up 42% quarter-over-quarter.
- 20 funds opened new Niagen Bioscience positions in Q3 2024 and 8 closed out, a net change of +12 holders.
- The largest Niagen Bioscience buyer in Q3 2024 was BlackRock, an estimated $879K added.
- The largest Niagen Bioscience seller in Q3 2024 was Millennium Management, an estimated $525K sold.
Based on aggregated 13F filings for Q3 2024.